論文原著

英　文

• Akazawa Y, Yasukochi S, Takei K, Takigiku K, Inamura N, Takagi K, Pooh RK, Yoshimatsu J, Kamei Y, Tamaru S, Yamamoto Y, Miyake T, Hata T; Fetal HQ Study Group.
  Normal values and distribution of ventricular global longitudinal strain in 513 healthy fetuses measured by two-dimensional speckle-tracking echocardiography: a multi-institutional cohort study.
  Heart Vessels. 2024 Oct 30. doi: 10.1007/s00380-024-02477-4. Online ahead of print
• Inoue K, Hoshino E, Shiratori T, Sasaki A, Kajihara T, Kozawa E.
  A large benign struma ovarii with atypical imaging findings.
  Radiol Case Rep. 19(11): 5447-5451, 2024
• Hasegawa K, Takahashi S, Ushijima K, Okadome M, Yonemori K, Yokota H, Vergote I, Monk BJ, Tewari KS, Fujiwara K, Li J, Jamil S, Paccaly A, Takehara K, Usami T, Aoki Y, Suzuki N, Kobayashi Y, Yoshida Y, Watari H, Seebach F, Lowy I, Mathias M, Fury MG, Oaknin A.
  Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.
  Cancer Med. 2024 Sep;13(18):e70236. doi: 10.1002/cam4.70236.
• Inoue K, Yasuda M, Hasegawa K, Kajihara T, Kozawa E.
  A case of ovarian endometrioid carcinoma: Atypical MR imaging.
  Radiol Case Rep. 19(6): 2245-2248, 2024
• Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators.
  Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
  Lancet. 403(10434): 1341-1350, 2024
• Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Toker S, Keefe SM, Lorusso D.
  Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.
  JAMA Oncol. 10(2): 185-192, 2024
• Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, Zale M, Okpara CE, Barresi G, McKenzie J, Makker V.
  Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
  Oncologist. 29(1): 25-35, 2024
• Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators.
  Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
  Lancet. 404(10460): 1321-1332, 2024
• Oaknin A, Ghamande SA, Kasamatsu Y, Gil-Martin M, Grau-Bejar JF, Garcia-Duran C, Sato M, Siddiqui A, Chaudhary SP, Vugmeyster Y, Hasegawa K.
  Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.
  Clin Cancer Res. 30(5): 975-983, 2024
• Nishijima A, Oda K, Hasegawa K, Koso T, Asada K, Ikeda Y, Taguchi A, Maeda D, Nagae G, Tsuji S, Tatsuno K, Uehara Y, Kurosaki A, Sato S, Tanikawa M, Sone K, Mori M, Ikemura M, Fujiwara K, Ushiku T, Osuga Y, Aburatani H.
  Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.
  Sci Rep. 14(1): 18797, 2024
• Takahashi Y, Fujiwara H, Yamamoto K, Takano M, Miyamoto M, Hasegawa K, Miwa M, Satoh T, Itagaki H, Hirakawa T, Mori-Uchino M, Nagai T, Hamada Y, Yamashita S, Yano H, Kato T, Fujiwara K, Suzuki M; GOTIC-VTE Trial Investigators.
  Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial.
  J Gynecol Oncol. 2024 Jul;35(4):e37. doi: 10.3802/jgo.2024.35.e37. Epub 2024 Jan 1.
• Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP, Zhou Q, Nishio S, Okamoto A, Wu X, Mileshkin L, Oaknin A, Ray-Coquard I, Hasegawa K, Jehl G, Vugmeyster Y, Zhang S, Bajars M, Yonemori K.
  Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.
  JAMA Oncol. 10(9): 1204-1211, 2024
• Doi T, Takahashi S, Aoki D, Yonemori K, Hara H, Hasegawa K, Takehara K, Harano K, Yunokawa M, Nomura H, Shimoi T, Horie K, Ogasawara A, Okame S.
  A first-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors.
  Cancer Chemother Pharmacol. 93(6): 605-616, 2024
• Itamochi H, Takeshima N, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Nishio S, Watari H, Yokoyama Y, Kase Y, Sumino S, Kato A, Suri A, Yasuoka T, Takehara K.
  Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.
  J Gynecol Oncol. 2024 Sep;35(5):e115. doi: 10.3802/jgo.2024.35.e115. Epub 2024 Jul 17.
• Aoki D, Tabata T, Yanagida S, Nakamura T, Kondo E, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Kato A, Suri A, Okamoto A, Sugiyama T.
  Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.
  J Gynecol Oncol. 2024 Sep;35(5):e114. doi: 10.3802/jgo.2024.35.e114.
• Nagao S, Nishio S, Takehara K, Sato S, Satoh T, Shimada M, Yamaguchi S, Tanabe H, Takano M, Horie K, Takei Y, Imai Y, Hibino Y, Hasegawa K, Takekuma M, Nakamura K, Takano H, Fujiwara K, Masuyama H.
  Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study.
  Int J Clin Oncol. 29(10): 1594-1601, 2024
• Mizoguchi C, Nishikawa T, Yoshida H, Yasuda M, Kato T, Hasegawa K, Yonemori K.
  HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma.
  J Gynecol Oncol. 2024 Jul 2. doi: 10.3802/jgo.2025.36.e14. Online ahead of print.
• Tsuchihashi S, Nagawa K, Shimizu H, Inoue K, Okada Y, Baba Y, Hasegawa K, Yasuda M, Kozawa E.
  Evaluation of Uterine Carcinosarcoma and Uterine Endometrial Carcinoma Using Magnetic Resonance Imaging Findings and Texture Features.
  Cureus. 2024 Mar 10;16(3):e55916. doi: 10.7759/cureus.55916. eCollection 2024 Mar.
• Kawabata-Iwakawa R, Iwasa N, Satoh K, Colinge J, Shimada M, Takeuchi S, Fujiwara H, Eguchi H, Oishi T, Sugiyama T, Suzuki M, Hasegawa K, Fujiwara K, Nishiyama M.
  Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.
  Int J Clin Oncol. 29(9): 1334-1346, 2024
• Ishida M, Sato S, Sato I, Yoshioka A, Uchida N, Mizunuma N, Hasegawa K, Onishi H.
  What can cause cancer patients to attempt suicide? Thiamine deficiency mimicking the symptoms of major depressive disorder.
  Palliat Support Care. 22(1): 205-208, 2024
• Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, González Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, Rosengarten O, Moore KN, Gómez-García EM, Tan D, Friedlander ML.
  How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
  Int J Gynecol Cancer. 2024 Oct 22:ijgc-2024-005976. doi: 10.1136/ijgc-2024-005976. Online ahead of print.
• Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators.
  Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
  N Engl J Med. 391(1): 44-55, 2024
• Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, Kim BG, Wang PH, Chang TC, Yamamoto K, Han S, McKenzie J, Orlowski RJ, Miura T, Makker V, Man Kim Y.
  Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
  J Gynecol Oncol. 2024 Mar;35(2):e40. doi: 10.3802/jgo.2024.35.e40. Epub 2024 Jan 19.
• Nakajima J, Yano M, Zaitsu S, Kamada K, Yabuno A, Hasegawa K, Kobayashi E, Yasuda M.
  Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma.
  Hum Pathol. 2024 Oct;152:105649. doi: 10.1016/j.humpath.2024.105649. Epub 2024 Aug 21.
• Hamasaki S, Kaneko G, Yabuno A, Miyama Y, Hiruta S, Hagiwara M, Shirotake S, Yasuda M, Oyama M.
  Robot-Assisted Partial Cystectomy Using the “Double Bipolar Method”.
  Cureus. 2024 Jun 3;16(6):e61610. doi: 10.7759/cureus.61610. eCollection 2024 Jun.
• Ogasawara A, Matsushita H, Tan TZ, Shintani D, Ye J, Nagao S, Demachi-Okamura A, Muraoka D, Kobayashi Y, Kakimi K, Yamaguchi R, Matsuo K, Yamamoto K, Fujiwara K, Huang RY, Tan DSP, Hasegawa K.
  Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
  Gynecol Oncol. 191: 124-131, 2024
• Miwa M, Kitagawa M, Asami Y, Kobayashi-Kato M, Watanabe T, Ogasawara A, Hiranuma K, Kato H, Saito M, Miyagi Y, Kato T, Yoshida H, Momozawa Y, Kohno T, Shiraishi K, Hasegawa K.
  Prevalence and outcomes of germline pathogenic variants of homologous recombination repair genes in ovarian cancer.
  Cancer Sci. 2024 Oct 10. doi: 10.1111/cas.16367. Online ahead of print.
• Sato S, Miura T, Ogasawara A, Shintani D, Yamaguchi S, Inui H, Yoshinaga A, Nishiyama M, Tsugane M, Hasegawa K.
  Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential.
  J Gynecol Oncol. 2024 Aug 2. doi: 10.3802/jgo.2025.36.e24. Online ahead of print.
• Okazawa-Sakai M, Sakai SA, Hyodo I, Horasawa S, Sawada K, Fujisawa T, Yamamoto Y, Boku S, Hayasaki Y, Isobe M, Shintani D, Hasegawa K, Egawa-Takata T, Ito K, Ihira K, Watari H, Takehara K, Yagi H, Kato K, Chiyoda T, Harano K, Nakamura Y, Yamashita R, Yoshino T, Aoki D.
  Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.
  J Gynecol Oncol. 2024 Oct 21. doi: 10.3802/jgo.2025.36.e38. Online ahead of print.
• Takano N, Takamura M, Mizuno Y, Mizuno Y, Tamaru S, Nakamura K, Soma H, Kajihara T.
  Genetic and histological analysis intraplacental choriocarcinoma: a case report.
  Med Mol Morphol. 57(2): 147-154, 2024
• Miyama Y, Kato T, Sato M, Yabuno A, Hasegawa K, Yasuda M.
  Cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases.
  Diagn Pathol. 2024 Jan 4;19(1):6. doi: 10.1186/s13000-023-01429-2.
• Inui H, Sato M, Yoshida H.
  Age Is a Risk Factor for Olaparib Dose Modification and Discontinuation in Patients With Ovarian Cancer.
  Cancer Diagn Progn. 4(4): 447-453, 2024
• Ito K, Nakamura K, Kajihara T, Shinozaki Y, Imura J, Sakuma H.
  Coexistence of complete intestinal tract, prostatic tissue, prostatic urethra and bladder structure in ovarian mature cystic teratoma: a case report.
  Med Mol Morphol. 2024 Nov 11. doi: 10.1007/s00795-024-00409-9. Online ahead of print.
• Jwa SC, Takahashi H, Tamaru S, Takamura M, Namba A, Kajihara T, Ishihara O, Kamei Y.
  Assisted reproductive technology-associated risk factors for retained products of conception.
  Fertil Steril. 121(3): 470-479, 2024
• Jwa SC, Tamaru S, Takamura M, Namba A, Kajihara T, Ishihara O, Kamei Y.
  Assisted reproductive technology-associated risk factors for placenta accreta spectrum after vaginal delivery.
  Sci Rep. 14(1): 7454, 2024
• Jwa SC, Takano N, Tamaru S, Kijima S, Uesato T, Matsubara K, Tanaka K, Doi K, Sameshima H, Iriyama T, Fukushima K, Hirata Y, Fujii T, Ishiwata I, Kamei Y, Seki H; Japan Association of Obstetricians and Gynecologists Telemedicine Proof-of-Concept Home Blood Pressure Research Group.
  Seasonal variation in home blood pressure during pregnancy and frequency of hypertensive disorders of pregnancy: a multicenter prospective study of home blood pressure measurements in pregnant women using information technology.
  Hypertens Res. 2024 Oct 23. doi: 10.1038/s41440-024-01952-9. Online ahead of print.
• Mizuno Y, Tamaru S, Tochigi H, Sato T, Kishi M, Ohtake A, Ishihara O, Kajihara T.
  Decidualized Endometrial Stromal Cells Promote Mitochondrial Beta-Oxidation to Produce the Octanoic Acid Required for Implantation.
  Biomolecules. 14(8): 1014, 2024

邦　文

• 山本　勉、高橋幸男、瀬戸　裕、西岡暢子、宮本純孝、小笠原美和、芦田　敬、石黒共人、高橋幸子、高井　泰、亀井良政、平田善康
  犯罪被害者等支援推進医療施設を受診した性被害者に関するアンケート調査報告　－4年間の経緯－
  埼玉産科婦人科学会雑誌54(1): 92-101, 2024
• 佐藤はづき、難波　聡、上村のぞみ、志倉絵理、鶴岡　恵、熊谷奈美、霞澤　亘、鷹野夏子、左　勝則、田丸俊輔、亀井良政
  非侵襲的出生前遺伝学的検査（NIPT）9年間の検討
  埼玉産科婦人科学会雑誌54(1): 69-75, 2024

論文総説

邦　文

• 亀井良政
  【産婦人科医のための感染症最新レクチャー】母子感染・周産期感染　梅毒
  臨床婦人科産科78(1): 92-97, 2024
• 梶原　健
  【これでマスター! 最新 産婦人科ホルモン療法】（第2章）A 生殖内分泌　生殖補助医療における排卵誘発とトリガー
  産科と婦人科91(Suppl): 136-141, 2024.
• 梶原　健
  【フローチャートでわかる　婦人科外来診療パーフェクトブック】症候からの鑑別診断　頻発月経、希発月経
  産婦人科の実際73(11): 1124-1128, 2024
• 永田一郎
  【子宮摘出と機能障害・機能温存・機能再建アップデート】術式別の機能再建　腟式子宮全摘術と腟式骨盤臓器脱手術（native tissue repair）　その有用性と手技上のtips and tricks
  産科と婦人科91(4): 433-448, 2024
• 難波　聡
  シン・産婦人科領域のスポーツ医学（第8回）　女性アスリートの新たな医学的課題　テストステロンと競技参加基準
  臨床スポーツ医学41(8): 868-871, 2024
• 難波　聡、松田貴雄
  シン・産婦人科領域のスポーツ医学（第6回）　妊娠中の運動に関する新知見　流産・早産のパラダイムシフトと妊娠中のスポーツ活動の許容
  臨床スポーツ医学41(6): 644-647, 2024
• 難波　聡、大竹　明
  【重篤な遺伝性疾患の着床前診断-患者ニーズと診断・治療の現状】疾患各論　ミトコンドリア病
  臨床婦人科産科78(2): 228-235, 2024
• 佐藤はづき、難波　聡
  シン・産婦人科領域のスポーツ医学（第5回）　妊娠中の運動に関する新知見　アスリートの妊娠中のトレーニングと産後復帰のための分娩形式
  臨床スポーツ医学41(5): 546-551, 2024
• 田丸俊輔
  【産婦人科医のための緊急対応サバイバルブック】緊急対応に備える　母体搬送をするとき、受けるときのポイント
  臨床婦人科産科78(4): 24-28, 2024
• 黒崎　亮
  【臨床力をグッとUPさせる「貧血」の知識-鉄代謝の基礎から管理・治療の具体策まで】婦人科領域の貧血　婦人科悪性腫瘍に伴う貧血の管理法
  臨床婦人科産科78(7): 625-631,2024
• 黒崎　亮
  【産婦人科医のための緊急対応サバイバルブック】婦人科編　術後合併症への対応法　術後の泌尿器合併症
  臨床婦人科産科78(4): 146-149, 2024
• 黒崎　亮
  【ICIを用いた各臓器がんの標準的治療と新規免疫療法の課題】婦人科腫瘍におけるがん免疫療法
  腫瘍内科33(2): 148-152, 2024
• 黒崎　亮
  Gynecologic Cancer　婦人科腫瘍　子宮体癌
  癌と化学療法51(2): 138-141, 2024
• 藪野　彰、長谷川幸清
  【後腹膜アプローチを活用した消化器内視鏡外科手術】外科解剖　婦人科からみた後腹膜領域の外科解剖
  手術78(6): 899-906, 2024
• 藪野　彰、長谷川幸清
  【婦人科がん化学療法の進化-最適レジメンと管理を考える-】レジメン選択に関する検査　DNAミスマッチ修復機能低下の検査
  産科と婦人科91(3): 227-234, 2024